OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 7 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).
Autologous Stem Cell Transplantation
Submission Deadline: October 15, 2021 (Open) Submit Now
Alessandra Picardi, PhD
Director, Division of Hematology and Stem Cell Transplantation Program, AORN Cardarelli Hospital, 80128 Naples, Italy;
Assistant Professor in Haematology at Biomedicine and Prevention Department, Tor Vergata University, Roma, Italy
Research Interest: Stem cell transplantation; autologous stem cell transplantation; allogeneic haematopoietic stem cell transplantation; bone marrow transplantation; transplant immune; leukemia
Nidhi Sharma, PhD
Internal Medicine, Division of Hematology, Ohio State University, Columbus, OH, USA
Research Interest: Graft vs host disease (GVHD); allogenic stem cell transplantation; autologous stem cell transplantation; stem cell transplantation
About This Topic
The number of autologous transplants recipients in the United States had steadily increased since 2000, rising up to 14.006 transplant procedures in 2018 (Blood and Marrow Research database). Autologous haemopoietic stem cell transplant (HSCT) still represents over 60% of transplant activity worldwide, although the new approved drugs and cellular therapies has slightly decreased the number of procedures for some haematological disease in the last 5 years. The most common indications for autologous HSCT remains multiple myeloma and lymphoma (Non Hodgkin and Hodgkin) in adult patients whereas its application is mainly related to solid tumors and refractory lymphomas in pediatric population.
The selection of optimal post-complete remission therapeutic strategy represents a crucial step for preventing relapse in most of haematological malignancies and the role of autologous HSCT, as valid alternative option, has been evaluated also in the setting of low risk Acute Leukemias. The low mortality rate allows its feasibility also in elderly patients with a trend to increased use up to 70-75 years.
Finally, autologous HSCT is the only treatment that is able to induce long-term, drug-free and symptom-free remission in several refractory autoimmune diseases, exploiting two main effects: 1) the immune system reset by renewing the CD4+ T cell compartment and 2) T cell receptor diversity and function restoring.
The scope of this volume will be to point out the main news about the conditioning regimens according to the underlying haematological or autoimmune disease,.in autologous HSCT.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.